Education
About Us
Working with TipRanks
Follow Us
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H (HK:2315)
:2315
Total Valuation
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H has a market cap or net worth of HK$10.67B. The enterprise value is HK$9.10B.
Market CapHK$10.67B
Enterprise ValueHK$9.10B
Share Statistics
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H has 110,781,920 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding110,781,920
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H’s return on equity (ROE) is 0.04 and return on invested capital (ROIC) is 6.09%.
Return on Equity (ROE)0.04
Return on Assets (ROA)0.01
Return on Invested Capital (ROIC)6.09%
Return on Capital Employed (ROCE)0.09
Revenue Per Employee877.76K
Profits Per Employee38.44K
Employee Count1,117
Asset Turnover0.41
Inventory Turnover2.11
Valuation Ratios
The current PE Ratio of Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H is 70.9. Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H’s PEG ratio is -0.87.
PE Ratio70.9
PS Ratio3.24
PB Ratio3.81
Price to Fair Value3.81
Price to FCF18.25
Price to Operating Cash Flow25.86
PEG Ratio-0.87
Income Statement
In the last 12 months, Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H had revenue of 980.45M and earned 33.54M in profits. Earnings per share was 0.08.
Revenue980.45M
Gross Profit761.52M
Operating Income164.37M
Pretax Income42.94M
Net Income33.54M
EBITDA303.80M
Earnings Per Share (EPS)0.08
Cash Flow
In the last 12 months, operating cash flow was 385.07M and capital expenditures -46.42M, giving a free cash flow of 338.66M billion.
Operating Cash Flow385.07M
Free Cash Flow338.66M
Free Cash Flow per Share3.06
Dividends & Yields
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.09
52-Week Price Change250.28%
50-Day Moving Average25.38
200-Day Moving Average16.65
Relative Strength Index (RSI)44.05
Average Volume (3m)521.33K
Important Dates
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H upcoming earnings date is Apr 1, 2026, TBA (Confirmed).
Last Earnings DateAug 28, 2025
Next Earnings DateApr 1, 2026
Ex-Dividend Date―
Financial Position
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H as a current ratio of 1.53, with Debt / Equity ratio of 68.85%
Current Ratio1.53
Quick Ratio1.33
Debt to Market Cap0.13
Net Debt to EBITDA0.62
Interest Coverage Ratio1.79
Taxes
In the past 12 months, Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H has paid 9.40M in taxes.
Income Tax9.40M
Effective Tax Rate0.22
Enterprise Valuation
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H EV to EBITDA ratio is 11.08, with an EV/FCF ratio of 19.33.
EV to Sales3.43
EV to EBITDA11.08
EV to Free Cash Flow19.33
EV to Operating Cash Flow15.94
Balance Sheet
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H has HK$486.84M in cash and marketable securities with HK$614.18M in debt, giving a net cash position of -HK$127.34M billion.
Cash & Marketable SecuritiesHK$486.84M
Total DebtHK$614.18M
Net Cash-HK$127.34M
Net Cash Per Share-HK$1.15
Tangible Book Value Per ShareHK$2.06
Margins
Gross margin is 79.48%, with operating margin of 16.76%, and net profit margin of 3.42%.
Gross Margin79.48%
Operating Margin16.76%
Pretax Margin4.38%
Net Profit Margin3.42%
EBITDA Margin30.99%
EBIT Margin13.73%
Analyst Forecast
The average price target for Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H is HK$27.00, which is 11.43% higher than the current price. The consensus rating is Hold
Price TargetHK$27.00
Price Target Upside7.66% Upside
Analyst ConsensusHold
Analyst Count0
Revenue Growth Forecast48.38%
EPS Growth Forecast―